These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 29376867)

  • 1. Antemortem-Postmortem Correlation of Florbetapir (18F) PET Amyloid Imaging with Quantitative Biochemical Measures of Aβ42 but not Aβ40.
    Beach TG; Maarouf CL; Intorcia A; Sue LI; Serrano GE; Lu M; Joshi A; Pontecorvo MJ; Roher AE
    J Alzheimers Dis; 2018; 61(4):1509-1516. PubMed ID: 29376867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
    Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
    Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.
    Ikonomovic MD; Klunk WE; Abrahamson EE; Mathis CA; Price JC; Tsopelas ND; Lopresti BJ; Ziolko S; Bi W; Paljug WR; Debnath ML; Hope CE; Isanski BA; Hamilton RL; DeKosky ST
    Brain; 2008 Jun; 131(Pt 6):1630-45. PubMed ID: 18339640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method.
    Korecka M; Figurski MJ; Landau SM; Brylska M; Alexander J; Blennow K; Zetterberg H; Jagust WJ; Trojanowski JQ; Shaw LM;
    Clin Chem; 2020 Apr; 66(4):587-597. PubMed ID: 32087019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of amyloid plaques by radioligands for Abeta40 and Abeta42: potential imaging agents in Alzheimer's patients.
    Kung MP; Skovronsky DM; Hou C; Zhuang ZP; Gur TL; Zhang B; Trojanowski JQ; Lee VM; Kung HF
    J Mol Neurosci; 2003 Feb; 20(1):15-24. PubMed ID: 12663930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Aβ analysis using magnetically-labeled immunoassays and PET
    Wu KY; Hsiao IT; Chen CH; Liu CY; Hsu JL; Huang SY; Yen TC; Lin KJ
    Sci Rep; 2018 Feb; 8(1):2739. PubMed ID: 29426824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of β-Amyloid, Microglial Activation, Cortical Thickness, and Metabolism in Older Adults Without Dementia.
    Cai Y; Shi D; Lan G; Chen L; Jiang Y; Zhou L; Guo T;
    Neurology; 2024 Apr; 102(7):e209205. PubMed ID: 38489560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients.
    Svedberg MM; Hall H; Hellström-Lindahl E; Estrada S; Guan Z; Nordberg A; Långström B
    Neurochem Int; 2009; 54(5-6):347-57. PubMed ID: 19162107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diversity in Aβ deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis.
    Xu G; Fromholt SE; Chakrabarty P; Zhu F; Liu X; Pace MC; Koh J; Golde TE; Levites Y; Lewis J; Borchelt DR
    Acta Neuropathol Commun; 2020 Apr; 8(1):43. PubMed ID: 32252825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron treatment inhibits Aβ42 deposition in vivo and reduces Aβ42/Aβ40 ratio.
    Shen X; Liu J; Fujita Y; Liu S; Maeda T; Kikuchi K; Obara T; Takebe A; Sayama R; Takahashi T; Matsue A; Sera K; Michikawa M; Komano H; Zou K
    Biochem Biophys Res Commun; 2019 May; 512(4):653-658. PubMed ID: 30791980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Derivation and utility of an Aβ-PET pathology accumulation index to estimate Aβ load.
    Leuzy A; Lilja J; Buckley CJ; Ossenkoppele R; Palmqvist S; Battle M; Farrar G; Thal DR; Janelidze S; Stomrud E; Strandberg O; Smith R; Hansson O
    Neurology; 2020 Nov; 95(21):e2834-e2844. PubMed ID: 33077542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlations between plasma and PET beta-amyloid levels in individuals with subjective cognitive decline: the Fundació ACE Healthy Brain Initiative (FACEHBI).
    de Rojas I; Romero J; Rodríguez-Gomez O; Pesini P; Sanabria A; Pérez-Cordon A; Abdelnour C; Hernández I; Rosende-Roca M; Mauleón A; Vargas L; Alegret M; Espinosa A; Ortega G; Gil S; Guitart M; Gailhajanet A; Santos-Santos MA; Moreno-Grau S; Sotolongo-Grau O; Ruiz S; Montrreal L; Martín E; Pelejà E; Lomeña F; Campos F; Vivas A; Gómez-Chiari M; Tejero MA; Giménez J; Pérez-Grijalba V; Marquié GM; Monté-Rubio G; Valero S; Orellana A; Tárraga L; Sarasa M; Ruiz A; Boada M;
    Alzheimers Res Ther; 2018 Nov; 10(1):119. PubMed ID: 30497535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E4 promotes the early deposition of Abeta42 and then Abeta40 in the elderly.
    Walker LC; Pahnke J; Madauss M; Vogelgesang S; Pahnke A; Herbst EW; Stausske D; Walther R; Kessler C; Warzok RW
    Acta Neuropathol; 2000 Jul; 100(1):36-42. PubMed ID: 10912918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemically treated plasma Aβ is a potential blood-based biomarker for screening cerebral amyloid deposition.
    Park JC; Han SH; Cho HJ; Byun MS; Yi D; Choe YM; Kang S; Jung ES; Won SJ; Kim EH; Kim YK; Lee DY; Mook-Jung I
    Alzheimers Res Ther; 2017 Mar; 9(1):20. PubMed ID: 28330509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. beta-amyloid (Abeta)42(43), abeta42, abeta40 and apoE immunostaining of plaques in fatal head injury.
    Horsburgh K; Cole GM; Yang F; Savage MJ; Greenberg BD; Gentleman SM; Graham DI; Nicoll JA
    Neuropathol Appl Neurobiol; 2000 Apr; 26(2):124-32. PubMed ID: 10840275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
    Rippon B; Palta P; Tahmi M; Sherwood G; Soto L; Cespedes S; Mesen Y; He H; Laing K; Moreno H; Teresi J; Razlighi Q; Brickman AM; Zetterberg H; Luchsinger JA
    J Alzheimers Dis; 2022; 87(3):1229-1238. PubMed ID: 35466933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images.
    Joshi AD; Pontecorvo MJ; Lu M; Skovronsky DM; Mintun MA; Devous MD
    J Nucl Med; 2015 Nov; 56(11):1736-41. PubMed ID: 26338898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
    Fleisher AS; Chen K; Liu X; Roontiva A; Thiyyagura P; Ayutyanont N; Joshi AD; Clark CM; Mintun MA; Pontecorvo MJ; Doraiswamy PM; Johnson KA; Skovronsky DM; Reiman EM
    Arch Neurol; 2011 Nov; 68(11):1404-11. PubMed ID: 21747008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.